Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Free Cash Flow: 2011-2024

Historic Free Cash Flow for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to -$391.5 million.

  • Agios Pharmaceuticals' Free Cash Flow fell 5.99% to -$89.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.1 million, marking a year-over-year decrease of 25.44%. This contributed to the annual value of -$391.5 million for FY2024, which is 31.80% down from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Free Cash Flow of -$391.5 million as of FY2024, which was down 31.80% from -$297.1 million recorded in FY2023.
  • Agios Pharmaceuticals' 5-year Free Cash Flow high stood at -$297.1 million for FY2023, and its period low was -$413.1 million during FY2021.
  • Moreover, its 3-year median value for Free Cash Flow was -$314.4 million (2022), whereas its average is -$334.3 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Free Cash Flow plummeted by 35.49% in 2021, and later rose by 23.90% in 2022.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' Free Cash Flow stood at -$304.9 million in 2020, then slumped by 35.49% to -$413.1 million in 2021, then rose by 23.90% to -$314.4 million in 2022, then climbed by 5.50% to -$297.1 million in 2023, then tumbled by 31.80% to -$391.5 million in 2024.